论文部分内容阅读
该文系统评价了非小细胞肺癌(NSCLC)不同分期治疗上的成本效益,并将分析重点放在新近批准的药物制剂上。对于处于局限期的病人,辅助性化疗似乎更具成本效益,但公开发表的数据较少。对于局部晚期肺癌,综合治疗(化疗,手术和/或放疗)可能是具有成本效益的,但目前缺乏高质量的经济评价。在可以接受的增量成本效益下,三代化疗可成为治疗晚期非小细胞肺癌病人的一线治疗。在二线治疗中,新的制剂(多西紫杉醇,培养曲塞和埃罗替尼)具有令人满意的成本效益。该文提示:当病人身体状态不错时,大部分非小细胞肺癌的治疗是具备成本效益的;多数情况下,每一个生命年病人的增量成本效益比率低于50 000美元。
The article systematically evaluated the cost-effectiveness of different staging of non-small cell lung cancer (NSCLC) and focused the analysis on newly approved pharmaceutical preparations. Adjuvant chemotherapy appears to be more cost-effective for patients in limited periods, but there are fewer published data. For locally advanced lung cancer, combination therapy (chemotherapy, surgery, and / or radiotherapy) may be cost-effective but there is currently a lack of high-quality economic evaluation. With acceptable incremental cost benefits, three generations of chemotherapy can be the first-line treatment for patients with advanced non-small cell lung cancer. In second-line treatment, the new formulations (docetaxel, trastuzumab and erlotinib) are satisfactorily cost-effective. The paper suggests that the treatment of most NSCLC is cost-effective when the patient is in good health and in most cases the incremental cost-benefit ratio for each patient is less than $ 50,000.